All Pathways
Cardiothoracic SurgeryEmergency

Type B Aortic Dissection Management (EACTS/STS 2024)

Type B Aortic Dissection Management (EACTS/STS 2024): Type B Aortic Dissection → Confirm Diagnosis → Complicated vs Uncomplicated? → Complicated TBAD → ...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Type B Aortic Dissection

    Dissection originating distal to left subclavian (DeBakey III / Stanford B)

    1. Action

      Confirm Diagnosis

      CTA chest/abdomen/pelvis (gold standard)

      • CTA: identify entry tear, extent, branches involved
      • Entry tear usually just distal to L subclavian
      • ASSESS FOR:
      • • Branch vessel involvement
      • • Malperfusion syndromes
      • • Maximum aortic diameter
      • • False lumen status (patent, thrombosed, partial)
      1. Decision

        Complicated vs Uncomplicated?

        Key determinant of management

        • COMPLICATED (any of):
        • • Malperfusion (renal, mesenteric, limb)
        • • Rupture or impending rupture
        • • Refractory pain/hypertension
        • • Rapid expansion
        • UNCOMPLICATED:
        • • Stable patient, no malperfusion
        1. Action

          Complicated TBAD

          Requires urgent intervention

          • TEVAR is first-line (Class I)
          • Goals:
          • • Cover entry tear
          • • Restore true lumen flow
          • • Relieve malperfusion
          • May need adjuncts:
          • • Branch vessel stenting
          • • Fenestration (rare)
          1. Action

            TEVAR Procedure

            Thoracic endovascular aortic repair

            • COVERAGE:
            • • Cover primary entry tear
            • • Landing zones: Zone 2-4 typically
            • • May need L subclavian coverage (revascularize if needed)
            • GOAL: Promote false lumen thrombosis
            • and aortic remodeling
            • Success rate: >90% for acute complicated
            1. Action

              Long-Term Medical Management

              All patients, lifelong

              • Blood pressure control (<130/80)
              • Beta-blocker preferred
              • Smoking cessation
              • Lipid management
              • SURVEILLANCE:
              • • CTA at 1, 3, 6, 12 months
              • • Then annually
              • • Watch for aneurysmal degeneration
              1. Action

                Long-Term Surveillance

                Critical for all TBAD patients

                • 30% develop aneurysmal degeneration
                • requiring intervention
                • RED FLAGS on imaging:
                • • Aortic growth >5mm/year
                • • New dissection extension
                • • Persistent patent false lumen
                • • End-organ malperfusion
                1. Outcome

                  Stable / Remodeled

                  Continue lifelong surveillance and medical therapy

            2. Action

              Open Surgical Repair

              Reserved for specific indications

              • INDICATIONS:
              • • TEVAR not feasible (anatomy)
              • • Connective tissue disorder (debated)
              • • Aneurysmal degeneration >55-60mm
              • • Chronic dissection with symptoms
              • Approach: Left thoracotomy, CPB,
              • deep hypothermia, graft replacement
        2. Action

          Uncomplicated TBAD

          Optimal medical therapy first-line

          • IMPULSE CONTROL (immediate):
          • • Target HR <60 bpm
          • • Target SBP 100-120 mmHg
          • • Beta-blocker FIRST (esmolol, labetalol)
          • • Then add vasodilators if needed
          • Pain control (avoid tachycardia)
          • ICU monitoring 48-72h minimum
          1. Action

            Assess High-Risk Features

            May benefit from early TEVAR

            • HIGH-RISK ANATOMY:
            • • Entry tear >10mm
            • • Aortic diameter >40mm at presentation
            • • False lumen diameter >22mm
            • • Patent false lumen with partial thrombosis
            • • Connective tissue disorder (Marfan, etc)
            • Consider TEVAR in subacute phase (2-6 weeks)
            • if high-risk features present

Guideline Source

EACTS/STS 2024 Aortic Guidelines - Type B Dissection

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • TEVAR for uncomplicated TBAD still debated (INSTEAD, ADSORB trials)
  • Optimal timing of intervention in subacute phase unclear
  • Definition of 'high-risk features' varies between guidelines
  • Medical management success varies by center

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Type B Aortic Dissection Management (EACTS/STS 2024)?

The Type B Aortic Dissection Management (EACTS/STS 2024) is a emergency clinical algorithm for Cardiothoracic Surgery. It provides a structured decision tree to guide clinical decision-making, based on EACTS/STS 2024 Aortic Guidelines - Type B Dissection.

What guideline is the Type B Aortic Dissection Management (EACTS/STS 2024) based on?

This algorithm is based on EACTS/STS 2024 Aortic Guidelines - Type B Dissection (DOI: 10.1016/j.athoracsur.2024.01.021).

What are the limitations of the Type B Aortic Dissection Management (EACTS/STS 2024)?

Known limitations include: TEVAR for uncomplicated TBAD still debated (INSTEAD, ADSORB trials); Optimal timing of intervention in subacute phase unclear; Definition of 'high-risk features' varies between guidelines; Medical management success varies by center. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Type B Aortic Dissection Management (EACTS/STS 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free